Select Page

Company to buy

  • Industry: Pharmaceutical
  • Subindustry: Clinical Research Organisation (CRO)
  • Revenue: £5-£10 million
  • EBITDA: £1-£2 million
  • Location: United Kingdom
  • #CFIE PHB341

Overview of the buyer for the UK-based CRO

The buyer is keen to establish a long-term partnership with a medium-sized Clinical Research Organisation (CRO) in the UK, particularly appealing to owners who are seeking a succession plan to ensure continued growth. Led by an experienced leader in the healthcare sector, specialising in medical devices and biotechnology, the investment entity is poised for a smooth transition, as the buyer is prepared to assume the role of CEO. Furthermore, the team comprises experts in international mergers and acquisitions (M&A) as well as private equity, all of whom possess substantial transactional experience, thereby enhancing the prospects for a successful collaboration.

Strategy of the buyer for the UK-based CRO

The buyer is seeking to acquire profitable UK-based Contract Research Organisations (CROs) with a turnover ranging from £5 million to £10 million and an EBITDA of between £1 million and £2 million. They are particularly interested in companies that possess solid foundations and demonstrate significant growth potential, especially in the realms of early-phase clinical trials or niche services. Following the acquisition, the buyer plans to provide management with expert support to enhance growth and efficiency while prioritising cultural alignment and staff retention. Their overarching goal is to uphold the legacy and quality of these organisations while simultaneously creating new opportunities for expansion and increased value.

 

Subscribe as an interested seller


Contact us to get details about this opportunity to sell a UK-based CRO

 

Activities of suitable targets

  • Mid-sized Contract Research Organizations (CROs) that specialize in early-phase clinical trials or focus on specific therapeutic areas such as oncology, rare diseases, or personalized medicine.
  • Organizations with consistent revenue streams, typically ranging from £5 million to £10 million, and resilient EBITDA margins between £1 million and £2 million.
  • Companies that have an established client base, strong operational processes, and a skilled workforce.
  • Firms seeking a strategic partner for succession planning, growth, or operational optimization.
  • Entities that are open to partnerships, emphasizing cultural alignment, staff retention, and long-term stewardship.

Highlights of the buyer for the UK-based CRO

  • Experienced leadership prepared to engage actively in daily operations
  • Strong focus on maintaining continuity for clients and employees
  • Supported by a team with over £5 billion in combined transaction experience
  • Tailored transition plans crafted to meet the seller’s needs
  • Emphasis on cultural fit and long-term growth rather than immediate financial extraction
  • Seeking opportunities in the UK with a focused and region-specific approach

More information on this buyer for UK-based CRO

Please get in touch if you are interested in learning more about this buyer for UK-based CRO. For more cro companies for sale please visit the section cro companies for sale. For other cro buyers, please visit the section cro companies wanted. If you are instead interested in pharma companies for sale, please visit the pharma companies for sale section. For pharma buyers, please visit the section pharma companies wanted.

Subscribe as a seller for this CRO buyer

en_GBEnglish (UK)